Philips and MD Anderson collaborate to facilitate personalized oncology treatments and clinical trial matching based on genom...
16 Junio 2020 - 8:00AM
Philips and MD Anderson collaborate to facilitate personalized
oncology treatments and clinical trial matching based on genomic
markers
June 16, 2020
Philips connects oncologists and pathologists around the world
to MD Anderson’s Precision Oncology Decision Support (PODS) system
of actionable clinical information
Amsterdam, the Netherlands, and Houston, US –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology, and The University of Texas MD Anderson Cancer Center
today announced a collaboration to provide oncologists with
evidence-based therapy and clinical trial guidance through Philips’
oncology informatics solutions and MD Anderson’s Precision Oncology
Decision Support (PODS) system. This collaboration will allow
physicians around the world to personalize therapy based on the
patient’s genomic profile, with the aim of improving patient
care.
MD Anderson developed the PODS system as an evidence-based tool
to facilitate therapeutic decision-making at the point of care. The
system provides actionable clinical information, including approved
therapies and available clinical trials, based upon genetic
alterations within the tumor. Through the Philips solutions,
clinicians receive a unified view of therapies and clinical trials
in the context of their patient’s unique tumor, helping them make
an evidence-based decision for their patient’s treatment.
“We developed PODS to enable physicians to better understand and
act on genetic variations within each patient’s tumor, making it
easier to provide the best treatments possible,” said Funda
Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics
at MD Anderson. “Through our collaboration with Philips, we hope to
share our clinical experience with physicians around the world and
contribute to improving care for patients globally.”
Today, pathologists and oncologists are faced with the
challenges of keeping abreast of the increasing number of therapy
options and the rapid advances in genomic testing, the molecular
findings of which require increasingly specialized expertise to
interpret. The growing amount of evidence for newly approved
targeted and immune-oncology therapies necessitates solutions to
simplify the complexity. Philips and MD Anderson aim to help
pathologists and oncologists serve their patients and provide them
with therapeutic options and relevant clinical trials based on
tumor markers.
“Driven by the latest therapy breakthroughs, a deeper
understanding of cancer biology and an increasing number of
clinical trials, oncology practices can provide more options than
ever for many patients,” said Louis Culot, General Manager of
Oncology Informatics at Philips. “Broadening our long-standing
collaboration with MD Anderson, Precision Oncology Decision Support
becomes available to physicians through the Philips oncology
informatics solution, providing the latest actionable information
that supports their confident clinical decision-making.“
End-to-end oncology carePhilips oncology
informatics and genomics solutions empower end-to-end oncology care
and evidence-based decisions. The solutions unify and streamline
oncology care across the patient journey, enabling clinical team
collaboration to drive best practices, clinical quality, and
decision support from early-detection, treatment guidance, and
follow-up care.
For further information, please contact:
Hans DriessenPhilips Global Press OfficeTel. : +31 6
10610417E-mail: hans.driessen@philips.comTwitter:
@hansdriessen_ph
Clayton BoldtMD Anderson Public Relations OfficeTel. :
+1-713-792-9518E-mail: crboldt@mdanderson.orgTwitter:
@MDAndersonNews
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people’s health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About MD Anderson The University of Texas MD
Anderson Cancer Center in Houston ranks as one of the world’s most
respected centers focused on cancer patient care, research,
education and prevention. The institution’s sole mission is to end
cancer for patients and their families around the world. MD
Anderson is one of only 51 comprehensive cancer centers designated
by the National Cancer Institute (NCI). MD Anderson is ranked No.1
for cancer care in U.S. News & World Report’s “Best Hospitals”
survey. It has ranked as one of the nation’s top two hospitals for
cancer care since the survey began in 1990, and has ranked first 15
times in the last 18 years. MD Anderson receives a cancer center
support grant from the NCI of the National Institutes of Health
(P30 CA016672).
- Physicians discuss patient treatment options
- Oncology informatics provides actionable information to
physicians
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024